HSK31679

Phase 2Small molecule

Haisco Pharmaceutical Group Co., Ltd.

HSK31679 is one of 86 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseActive, not recruiting

Non-Alcoholic SteatohepatitisActive, not recruiting

Non-Alcoholic Steatohepatitis (NASH)Completed

Alcoholic Fatty Liver DiseasePhase 2

Active, not recruiting

Non-Alcoholic SteatohepatitisPhase 2

Active, not recruiting

Non-Alcoholic Steatohepatitis (NASH)Phase 2

Completed

Competition

Competitive Landscape

96 competitors in Non-Alcoholic Steatohepatitis

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

4 2

Victoza

Novo Nordisk

Phase 3

2 3

Farxiga

AstraZeneca

Phase 2

1 4

Uloric

Takeda

Phase 2

1 5

Avandia

Alnylam Pharmaceuticals

Phase 2

1 6

Efruxifermin

Akero Therapeutics

Phase 3

1 7

Diosmin

TTanta University

Phase 3

1 8

Metadoxine

AAlcobra Ltd.

Phase 3

1 9

Dipeptidyl Peptidase 4 Inhibitor

Boehringer Ingelheim

Phase 3

1 10

Zetia

OOrganon and Co

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

TED1 trial

Ascending Single-Dose and Multiple-Dose Study to Evaluate HSK31679 in Healthy Subjects and Subjects With Elevated LDL-C

Completed· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT05531097·96 enrolled

Metabolism1 trial

Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK31679 in Healthy Adult Male Volunteers.

Unknown status·XXizang Haisco Pharmaceutical Co., Ltd·Phase 1·NCT06258746·6 enrolled

Alcoholic Fatty Liver Disease1 trial

Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）

Completed· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT05795517·210 enrolled

Non-alcoholic Steatohepatitis (NASH)1 trial

A Multicenter, Double-blind, Placebo Randomized , Phase2b Study to Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH).

Completed· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT06168383·186 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for HSK31679. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HSK31679 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HSK31679. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Haisco Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Haisco Pharmaceutical Group Co., Ltd.

HSK31679

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

TED1 trial

Metabolism1 trial

Alcoholic Fatty Liver Disease1 trial

Non-alcoholic Steatohepatitis (NASH)1 trial

References

Drug Info

Quick Facts

Related News